ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
bringing together oncologists and oncology-focused healthcare professionals across the Empire State
Meetings & Education
State Society Education Series
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
Financial Advocacy & Patient Assistance
ESHOS Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
Medicare Coverage Established for MRD Testing for ALL, Multiple Myeloma
On January 17, Adaptive Biotechnologies announced that Palmetto GBA has established coverage of the clonoSEQ Assay for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL). clonoSEQ is the only test authorized by the U.S. Food and Drug Administration (FDA) to detect and monitor minimal residual disease (MRD) in myeloma and ALL using DNA from a patient’s bone marrow sample. The article is effective immediately and enables national coverage of Medicare patients undergoing testing.
Read the Adaptive Biotechnologies press release here